{"id":"W2766941538","doi":"10.1016/j.ahj.2017.09.020","title":"Apixaban following acute coronary syndromes in patients with prior stroke: Insights from the APPRAISE-2 trial","year":2017,"lang":"en","type":"article","venue":"American Heart Journal","topic":"Acute Ischemic Stroke Management","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"ca_institutions":"Canadian Heart Research Centre; University of Toronto","funders":"Pfizer; Bristol-Myers Squibb","keywords":"Medicine; Stroke (engine); Apixaban; Internal medicine; Myocardial infarction; Hazard ratio; Placebo; Cardiology; Diabetes mellitus; Cause of death; Proportional hazards model; Disease; Atrial fibrillation; Confidence interval; Rivaroxaban; Warfarin; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001708755,0.001397252,0.00347426,0.0002598049,0.0003065451,0.002018669,0.0006421611,0.001430283,0.002701655],"category_scores_gemma":[0.004280356,0.0004226769,0.002369649,0.0004522557,0.0006065628,0.001528765,0.000679318,0.003443688,0.000516351],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004838876,"about_ca_system_score_gemma":0.0005820853,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007138093,"about_ca_topic_score_gemma":0.002093266,"domain_scores_codex":[0.999231,0.0003779659,0.00007409841,0.0001193687,0.00009494711,0.0001026237],"domain_scores_gemma":[0.9987028,0.0004812539,0.0003789146,0.0001127733,0.00007698909,0.0002471624],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.8580093,0.003276754,0.0360541,0.004661219,0.01817733,0.0006496484,0.0002363429,0.001290437,0.003126185,0.001354062,0.01056103,0.06260356],"study_design_scores_gemma":[0.7522963,0.025568,0.1780516,0.001075406,0.0251474,0.0009630686,0.0003663648,0.002052504,0.0008274062,0.003002226,0.01046894,0.0001808686],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9294785,0.05475969,0.0004478198,0.003770513,0.0007277686,0.0005128064,0.002312999,0.0000769977,0.007912886],"genre_scores_gemma":[0.9683557,0.02071883,0.0006658185,0.002119969,0.001553368,0.0005921649,0.004186373,0.00002717547,0.001780658],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00347426,"threshold_uncertainty_score":0.009037971,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01701777271345544,"score_gpt":0.2894703660570455,"score_spread":0.27245259334359,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}